Evidence map›Paper›PMID 36647008›Full record

ArticleBMC bioinformatics2023

Identification of biomarkers predictive of metastasis development in early-stage colorectal cancer using network-based regularization.

Carolina Peixoto, Marta B Lopes, Marta Martins, Sandra Casimiro, Daniel Sobral, Ana Rita Grosso, Catarina Abreu, Daniela Macedo, Ana Lúcia Costa, Helena Pais and 21 more

Abstract read
In one paragraph

Article in BMC bioinformatics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prognostic value ofFrontiers in oncology · 2023
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Carolina PeixotoINESC-ID, Instituto Superior Técnico, Universidade de Lisboa, Rua Alves Redol 9, 1000-029, Lisbon, Portugal.
Marta B LopesNOVA Laboratory for Computer Science and Informatics (NOVA LINCS), NOVA School of Science and Technology, 2829-516, Caparica, Portugal.
Marta MartinsInstituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
Sandra CasimiroInstituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
Daniel SobralAssociate Laboratory i4HB - Institute for Health and Bioeconomy, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal.
Ana Rita GrossoAssociate Laboratory i4HB - Institute for Health and Bioeconomy, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516, Caparica, Portugal.
Catarina AbreuOncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
Daniela MacedoOncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
Ana Lúcia CostaOncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
Helena PaisOncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
Cecília AlvimOncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
André MansinhoInstituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
Pedro FilipeOncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
Pedro Marques da CostaOncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
Afonso FernandesInstituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
Paula BorralhoInstituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal.
Cristina FerreiraOncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
João MalaquiasOncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
António QuintelaOncology Division, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal.
Shannon KaplanIllumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
Mahdi GolkaramIllumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
Michael SalmansIllumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
Nafeesa KhanIllumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
Raakhee VijayaraghavanIllumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
Shile ZhangIllumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
Traci PawlowskiIllumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
Jim GodseyIllumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
Alex SoIllumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
Li LiuIllumina Inc., 5200 Illumina Way, San Diego, CA, 92122, USA.
Luís CostaInstituto de Medicina Molecular - João Lobo Antunes, Faculdade de Medicina de Lisboa, Avenida Professor Egas Moniz, 1649-028, Lisbon, Portugal. lmcosta@medicina.ulisboa.pt.
Susana VingaINESC-ID, Instituto Superior Técnico, Universidade de Lisboa, Rua Alves Redol 9, 1000-029, Lisbon, Portugal. susanavinga@tecnico.ulisboa.pt.

Funding

Fundação para a Ciência e a Tecnologia CEECINST/00102/2018,UIDB/04516/2020 (NOVA LINCS), and UIDB/00297/2020 (CMA)Fundação para a Ciência e a Tecnologia MONET (PTDC/CCI-BIO/4180/2020) and MATISSE (DSAIPA/DS/0026/2019)Fundação para a Ciência e a Tecnologia PD/BD/139146/2018Fundação para a Ciência e a Tecnologia PIC/IC/82821/2007Horizon 2020 951970 (OLISSIPO project)
6 · The paper itself

Abstract

Colorectal cancer (CRC) is the third most common cancer and the second most deathly worldwide. It is a very heterogeneous disease that can develop via distinct pathways where metastasis is the primary cause of death. Therefore, it is crucial to understand the molecular mechanisms underlying metastasis. RNA-sequencing is an essential tool used for studying the transcriptional landscape. However, the high-dimensionality of gene expression data makes selecting novel metastatic biomarkers problematic. To distinguish early-stage CRC patients at risk of developing metastasis from those that are not, three types of binary classification approaches were used: (1) classification methods (decision trees, linear and radial kernel support vector machines, logistic regression, and random forest) using differentially expressed genes (DEGs) as input features; (2) regularized logistic regression based on the Elastic Net penalty and the proposed iTwiner-a network-based regularizer accounting for gene correlation information; and (3) classification methods based on the genes pre-selected using regularized logistic regression. Classifiers using the DEGs as features showed similar results, with random forest showing the highest accuracy. Using regularized logistic regression on the full dataset yielded no improvement in the methods' accuracy. Further classification using the pre-selected genes found by different penalty factors, instead of the DEGs, significantly improved the accuracy of the binary classifiers. Moreover, the use of network-based correlation information (iTwiner) for gene selection produced the best classification results and the identification of more stable and robust gene sets. Some are known to be tumor suppressor genes (OPCML-IT2), to be related to resistance to cancer therapies (RAC1P3), or to be involved in several cancer processes such as genome stability (XRCC6P2), tumor growth and metastasis (MIR602) and regulation of gene transcription (NME2P2). We show that the classification of CRC patients based on pre-selected features by regularized logistic regression is a valuable alternative to using DEGs, significantly increasing the models' predictive performance. Moreover, the use of correlation-based penalization for biomarker selection stands as a promising strategy for predicting patients' groups based on RNA-seq data.

Indexed as

Colorectal NeoplasmsBiomarkersBiomarkers, TumorCell Adhesion MoleculesGPI-Linked ProteinsHumansLogistic ModelsBiomarkersBiomarkers, TumorCell Adhesion MoleculesGPI-Linked ProteinsOPCML protein, humanBiomarker selectionClassificationColorectal canceriTwinerRegularization

Identifiers

PMID36647008
PMCPMC9841719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.